To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
- Today’s Promising Areas of Cancer Research
- What is Cancer?
- A Broken Pipeline?
A Generation of Science at Risk
- ARISE Report
Early Career Scientists and High-Risk, High Reward Research - American Academy of Arts and Sciences
- Why We’re Losing the War on Cancer (And How To Win It)
Clifton Leaf - Fortune Magazine
June 5, 2010 > Successful treatment for metastatic melanoma
Jedd D. Wolchok, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘03-‘08) of Memorial Sloan-Kettering Cancer Center, New York, and colleagues reported the first treatment to improve overall survival in patients with metastatic melanoma. In a phase III clinical study, patients were treated with ipilimumab, which blocks a protein called CTLA-4 to promote an antitumor T-cell immune response. Overall survival was improved by 34.4% (10.1 months vs. 6.4 months). These findings were reported at the American Society of Clinical Oncology conference and in the New England Journal of Medicine.